-
Novateor Research Laboratories Limited Announces Filing of Annual Financial Results
Novateor Research Laboratories Limited announced that it has filed its annual financial results for the year ended March 31, 2023.
-
Novateor Research Laboratories Limited Announces Q4 and Fiscal Year 2023 Financial Results
Novateor Research Laboratories Limited announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.
-
Novateor Research Laboratories Limited Announces Collaboration with Leading Healthcare Provider
Novateor Research Laboratories Limited announced a collaboration with a leading healthcare provider to develop and commercialize a new diagnostic test for a rare genetic disorder.
-
Novateor Research Laboratories Limited Receives Grant for Innovative Research Project
Novateor Research Laboratories Limited announced that it has received a grant from the National Institutes of Health (NIH) for an innovative research project.
-
Novateor Research Laboratories Limited Announces Strategic Partnership with Global Pharmaceutical Company
Novateor Research Laboratories Limited announced a strategic partnership with a global pharmaceutical company to develop and commercialize a new drug for cancer treatment.
-
Novateor Research Laboratories Limited Promoted on the MSE (SME) Platform
Novateor Research Laboratories Limited has recently been promoted from MSE (SME) to MSE (Main) platform.
-
Novateor Research Laboratories Limited Signs MoU with AFCONS
Novateor Research Laboratories Limited has signed a Memorandum of Understanding (MoU) with AFCONS for Collaboration in conducting Research, Development and Marketing of Water Treatment Technologies.
-
Novateor Research Laboratories Limited Receives ISO 17025:2017 Accreditation
Novateor Research Laboratories Limited has received ISO 17025:2017 accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for its advanced analytical testing services.
-
Novateor Research Laboratories Limited Partners with Dalmia Bharat Limited
Novateor Research Laboratories Limited has partnered with Dalmia Bharat Limited to provide innovative and sustainable water treatment solutions for the cement industry.
-
Novateor Research Laboratories Limited Launches New Advanced Water Treatment Technology
Novateor Research Laboratories Limited has launched a new advanced water treatment technology that significantly reduces the energy consumption and operating costs associated with water treatment processes.
-
Novateor Research Laboratories Limited Announces Positive Pre-IND Meeting with FDA for NTR-301 for the Treatment of COVID-19
Novateor Research Laboratories Limited, a clinical-stage pharmaceutical company, today announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) during a pre-Investigational New Drug (IND) meeting for its lead drug candidate, NTR-301, for the treatment of COVID-19.
-
Novateor Research Laboratories Limited Announces Publication of NTR-301 Preclinical Data in Peer-Reviewed Journal
Novateor Research Laboratories Limited, a clinical-stage pharmaceutical company, today announced the publication of preclinical data for its lead drug candidate, NTR-301, in the peer-reviewed journal, Frontiers in Pharmacology.
-
Novateor Research Laboratories Limited Announces Initiation of Phase 2a Clinical Trial of NTR-301 for the Treatment of COVID-19
Novateor Research Laboratories Limited, a clinical-stage pharmaceutical company, today announced the initiation of a Phase 2a clinical trial to evaluate the safety and efficacy of NTR-301 for the treatment of COVID-19.
-
Novateor Research Laboratories Limited Announces Results for the Second Quarter Ended September 30, 2023
Novateor Research Laboratories Limited (BSE: 543263, NSE: NOVATEOR), a leading provider of contract research and development (R&D) services to the pharmaceutical and biotechnology industry, today announced its financial results for the second quarter ended September 30, 2023.
-
Novateor Research Laboratories Limited Announces Collaboration with Leading Pharmaceutical Company for Drug Discovery
Novateor Research Laboratories Limited (BSE: 543263, NSE: NOVATEOR), a leading provider of contract research and development (R&D) services to the pharmaceutical and biotechnology industry, today announced a collaboration with a leading pharmaceutical company for drug discovery.
-
Novateor Research Laboratories Limited Expands its Discovery Services Portfolio
Novateor Research Laboratories Limited (BSE: 543263, NSE: NOVATEOR), a leading provider of contract research and development (R&D) services to the pharmaceutical and biotechnology industry, today announced the expansion of its discovery services portfolio.
